SQLite Web: event_store.db

Update row 46520 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-15T02:18:53.247056+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:d468d62051074867","evidence_event_ids":["evt_df94cb42c862"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001193125-26-155495.txt","as_of":"2026-04-15T02:18:53.247056+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001193125-26-155495.txt","company":"Travere Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001193125-26-155495.txt","article_chars":2728,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_4cf95569ccdf36c1","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001193125-26-155495.txt","content_type":"text/plain","enriched_at":"2026-04-15T05:15:18.065281+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001193125-26-155495.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001193125-26-155495.txt","source_event_id":"evt_df94cb42c862","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"144","fp":"e9548adef534d77b","kind":"sec_filing","published_at":"20260414","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-14","2026-04-13","2026-02-04","2026-02-03","2013-02-20","2008-06-25"],"entities":[{"asset_class":"equity","name":"Travere Therapeutics, Inc.","relevance":"high","symbol":"TVTX","type":"issuer"},{"asset_class":"equity","name":"Christopher R. Cline","relevance":"high","symbol":"","type":"reporting_person"},{"asset_class":"other","name":"Morgan Stanley Smith Barney","relevance":"medium","symbol":"","type":"brokerage_firm"}],"event_type":"listing","information_gaps":["The provided text does not explicitly state the total number of shares sold across all line items beyond the individual quantities shown.","The provided text does not explicitly state the sale price(s) or aggregate proceeds.","The provided text does not specify the exact class of securities beyond \u201cCommon\u201d and the context of performance restricted stock units."],"key_facts":["SEC accession number: 0001193125-26-155495.","Conformed submission type: Form 144; filed as of date: 2026-04-14.","Subject company/issuer: Travere Therapeutics, Inc. (CIK 0001438533; SEC file number 001-36257).","Reporting owner: Christopher R. Cline (CIK 0001943192).","The filing states the shares represent the number required to be sold to cover tax withholding obligations upon settlement of vested performance restricted stock units.","The filing states the sale is mandated by the issuer\u2019s election under its equity incentive plans to fund tax withholding via a \u201csell to cover\u201d transaction with a brokerage firm designated by the issuer.","The filing includes a statement that the sale does not represent a discretionary trade by the reporting person.","Signature: /s/ Elizabeth E. Reed as attorney-in-fact for Christopher Cline."],"numeric_claims":[{"label":"Shares required to be sold (per filing line items)","value":"7239; 65; 1745; 7242 (as shown in the provided text)"}],"primary_claim":"Form 144 (accession 0001193125-26-155495) was filed on 2026-04-14 by Travere Therapeutics, Inc. for shares associated with Christopher Cline\u2019s tax withholding obligation in connection with vested performance restricted stock units.","relevance_score":0.45,"sentiment":"neutral","source_quality":"high","summary":"Travere Therapeutics, Inc. filed a Form 144 on 2026-04-14 related to a \u201csell to cover\u201d transaction for tax withholding upon settlement/vesting of performance restricted stock units by reporting person Christopher Cline.","topics":["SEC Form 144","share sale to cover","tax withholding","performance restricted stock units","equity incentive plan","Travere Therapeutics"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 144 \u00b7 Travere Therapeutics, Inc. \u00b7 Filed 20260414","ticker":"TVTX","tickers":["TVTX"],"title":"TVTX filed 144","url":"https://www.sec.gov/Archives/edgar/data/1438533/0001193125-26-155495.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel